Skip to main content

RT @uptoTate: Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase…

Social Author Name
Dr. Rachel Tate
Tweet Content
Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd #ACR19 @RheumNow abs#2877
Show on Archive Page
On
Display in Search Results
On
×